Last reviewed · How we verify

Iopofosine I 131 fractionated dose

Cellectar Biosciences, Inc. · Phase 2 active Small molecule

Iopofosine I 131 fractionated dose is a Small molecule drug developed by Cellectar Biosciences, Inc.. It is currently in Phase 2 development. Also known as: I-131-CLR1404, CLR 131.

At a glance

Generic nameIopofosine I 131 fractionated dose
Also known asI-131-CLR1404, CLR 131
SponsorCellectar Biosciences, Inc.
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Iopofosine I 131 fractionated dose

What is Iopofosine I 131 fractionated dose?

Iopofosine I 131 fractionated dose is a Small molecule drug developed by Cellectar Biosciences, Inc..

Who makes Iopofosine I 131 fractionated dose?

Iopofosine I 131 fractionated dose is developed by Cellectar Biosciences, Inc. (see full Cellectar Biosciences, Inc. pipeline at /company/cellectar-biosciences-inc).

Is Iopofosine I 131 fractionated dose also known as anything else?

Iopofosine I 131 fractionated dose is also known as I-131-CLR1404, CLR 131.

What development phase is Iopofosine I 131 fractionated dose in?

Iopofosine I 131 fractionated dose is in Phase 2.

Related